Skip to main content

Table 2 Adjusted and unadjusted odds ratios with ESBL-EC bacteraemia as the dependent variable

From: Differences in risk-factor profiles between patients with ESBL-producing Escherichia coli and Klebsiella pneumoniae: a multicentre case-case comparison study

 

ESBL-EC (%)

ESBL-KP (%)

Crude OR (95% CI)d/P value

Adjusted OR (95% CI)d

Demographics/acquisition

Male gendera

60/92 (65.2)

49/78 (62.8)

1.1 (0.6–2.2)

 

Median age (IQR)a

65.5 (53–76)

61.5 (38.5-75.5)

P = 0.01

 

High prevalence countrya

35/92 (38.0)

8/78 (10.3)

5.4 (2.2–13.7)

4.3 (1.6–11.6)

Pacific Islander

10/92 (10.9)

14/78 (17.9)

0.6 (0.2–1.4)

 

NZ Maori

2/92 (2.2)

6/78 (7.7)

0.3 (0.04–1.5)

 

LTCF residence

11/92 (12.0)

8/78 (10.3)

1.2 (0.4–3.5)

 

Community acquisitiona

35/92 (38.0)

6/78 (7.7)

7.4 (2.7–21.1)

7.9 (2.6–23.9)

Community onset infection

73/92 (79.3)

37/78 (47.4)

4.3 (2.1–8.8)

 

Recent ICU admissiona

5/92 (5.4)

14/78 (17.9)

0.3 (0.08–0.8)

 

Median hospital days (IQR)

1.5 (0–16)

9.5 (0–30.5)

P <0.0001

 

Hospital 1a

53/92 (57.6)

29/78 (37.1)

2.3 (1.2–4.5)

 

Hospital 2a

21/92 (22.8)

32/78 (41.0)

0.4 (0.2–0.9)

0.3 (0.1–0.7)

Hospital 3a

18/92 (19.6)

17/78 (21.8)

0.9 (0.4–2.0)

 

Source of bacteraemia

Urinary tract

49/92 (53.3)

33/78 (42.3)

1.6 (0.8–3.0)

 

Gastrointestinal

17/92 (18.5)

10/78 (12.8)

1.5 (0.6–3.9)

 

Central line

0/92 (1.1)

5/78 (7.7)

P = 0.02

 

Febrile neutropenia

6/92 (5.4)

13/78 (15.4)

0.3 (0.1–1.1)

 

Prostate biopsy related

8/92 (8.7)

0/78 (0)

P = 0.008

 

Bone and joint

0/92 (0)

3/78 (3.8)

P = 0.095

 

Respiratory tract

6/92(6.5)

3/78 (3.8)

1.7 (0.4–9.2)

 

Uncertainc

4/92 (4.3)

9/78 (11.5)

0.3 (0.1–1.3)

 

Comorbidities

Diabetes

22/92 (23.9)

14/78 (17.9)

1.4 (0.6–3.3)

 

Recurrent UTI

4/92 (4.3)

5/78 (6.4)

0.7 (0.1–3.0)

 

Long term IDC

11/92 (12.0)

12/78 (15.4)

0.7 (0.3–2.0)

 

Solid tumour

17/92 (18.5)

13/78 (16.7)

1.1 (0.5–2.7)

 

Haematological malignancy

12/92 (13.0)

16/78 (20.5)

0.6 (0.2–1.4)

 

Previous transplanta,b

1/92 (1.1)

7/78 (9.0)

0.1 (0.005–0.9)

0.06 (0.007–0.6)

Dialysis

4/92 (4.3)

2/78 (2.6)

1.7 (0.3–14.0)

 

CPDa

14/92 (15.2)

4/78 (5.1)

3.3 (1.0–12.6)

5.5 (1.5–20.1)

Median number comorbidities (IQR)

1 (1–3)

1 (1–2)

P = 0.39

 
  1. aIndicates that variable was included in the multivariate analysis.
  2. b4 patients with liver transplants, and 4 patients with hematopoietic stem cell transplants transplants (one additional patient with a liver transplant had separate episodes of ESBL-EC and ESBL-KP bacteremia).
  3. cUncertain sources were those where the treating clinician was unable determine the aetiology.
  4. dP values are included in this column for continuous variables and dichotomous variables for which an OR could not be calculated.
  5. IQR, interquartile range; LTCF, long term care facility; UTI, urinary tract infection; IDC, Indwelling urinary catheter; CPD, Chronic pulmonary disease.
Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us